Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600795 · ClinicalTrials.gov registry record
Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus
A clinical trial of Normal Pressure Hydrocephalus, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 21
- Enrollment target
- 1
- Study location
NCT00600795: Completed study of Normal Pressure Hydrocephalus, sponsored by Vanderbilt University Medical Center.
NCT00600795 is a study of Normal Pressure Hydrocephalus that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 21 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600795, a study of Normal Pressure Hydrocephalus, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Correlation of cerebrospinal fluid levels of transforming growth factor beta-1 with functional improvements after insertion of ventriculoperitoneal shunt for normal pressure hydrocephalus
Conditions Studied
Interventions
- OTHER CSF collection
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-06 |
What the finished NCT00600795 record still lists
NCT00600795 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 1 condition, with Normal Pressure Hydrocephalus appearing as the primary indexed condition, and to 1 intervention - of which CSF collection is the first listed.
NCT00600795 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00600795 about?
NCT00600795 is a clinical study titled "Prognostic Value of Transforming Growth Factor-Beta 1 in Normal Pressure Hydrocephalus". Correlation of cerebrospinal fluid levels of transforming growth factor beta-1 with functional improvements after insertion of ventriculoperitoneal shunt for normal pressure hydrocephalus
What is the current status of trial NCT00600795?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2008-01. Estimated completion is 2011-06.
What conditions does trial NCT00600795 study?
This clinical trial studies the following conditions: Normal Pressure Hydrocephalus.
What interventions are being tested in trial NCT00600795?
The interventions under investigation include: CSF collection (OTHER).
Who is sponsoring clinical trial NCT00600795?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00600795 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Normal Pressure Hydrocephalus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia